Curcumin effect on athresclerosis plaqua in coronary artery disease

Evaluation of Curcumin effect on plaque formation and plaque rupturing biomarkers in coronary artery disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112028276N1

Enrollment

Registered

2011-12-08

Start date

2011-12-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease. Atherosclerotic heart disease

Interventions

Intervention 1: Curcumin, Capsule 500 mg,1g/twice daily. Intervention 2: Placebo, Capsule 500 mg, 1g/twice daily.

Treatment - Drugs

Placebo

Curcumin, Capsule 500 mg,1g/twice daily

Placebo, Capsule 500 mg, 1g/twice daily

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: age more than 18 and diagnosis of coronary artery disease according to angiography results Exclusion criteria: severe renal or hepatic failure; having infectious disease; use of immunosuppressive or anti inalmmatory drugs; curcumin sensitivity; pregnancy and lactation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IL-18. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;CD40L. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;MMP-9. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;MPO. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;VCAM-1. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;MCP-1. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.	—

Measure

Time frame

IL-18. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;CD40L. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;MMP-9. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;MPO. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;VCAM-1. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.;MCP-1. Timepoint: Before and 2 month after begining of study. Method of measurement: Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mohammad reza Javadi

Tehran University of Medical Sciences

javadirctex1351@yahoo.com+98 218881415558

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026